Teclistamab Bispecific Antibody for Relapsed Multiple Myeloma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsed or refractory multiple myeloma are limited, with a low likelihood of regulatory approval and a significant unmet need for effective patient treatments, as evidenced by the low number of approved medicines and high mortality rate for the disease.
Innovation Solution
The development of teclistamab-cqyv, a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, is provided in a single-dose vial for injection, specifically indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, in combination with corticosteroids, H1 receptor antagonists, and antipyretics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple molecules are assessed in clinical trials to treat multiple myeloma, then the likelihood of finding an effective treatment increases, but the complexity and time required for drug development increases
Solution Approach 1:
The patent segments the drug development process by focusing on a specific bispecific antibody format (BCMA-directed CD3 T-cell engager) rather than assessing all possible molecules. This segmentation allows for more targeted clinical trials while maintaining high reliability in finding effective treatments for relapsed or refractory multiple myeloma.
2Reliability
If many molecules are tested in clinical trials, then the chance of identifying effective treatment increases, but the time and resources required increase significantly
Solution Approach 1:
The patent applies preliminary action by conducting extensive preclinical studies and selecting the most promising bispecific antibody candidate (teclistamab-cqyv) before entering clinical trials. This preliminary筛选 process reduces the number of candidates needing full clinical evaluation, thereby reducing time loss while maintaining high probability of success.
3Reliability
If a bispecific antibody is developed for relapsed or refractory multiple myeloma, then treatment efficacy improves, but the complexity of the pharmaceutical product increases
Solution Approach 1:
The bisspecific antibody teclistamab-cqyv performs multiple functions: it binds to BCMA on myeloma cells and simultaneously engages CD3 on T-cells, enabling both target recognition and immune activation in a single molecule. This multi-functionality improves treatment efficacy while the patent manages product complexity through standardized formulation and administration protocols.
Data Source
AI summary
Described herein are approved products and methods of using approved products for treating relapsed or refractory multiple myeloma in a patient. Also described herein are methods of selling or offering for sale an approved product.